Elanco

Elanco Animal Health Reports Second Quarter 2023 Results and Raises Full Year Guidance

Retrieved on: 
Monday, August 7, 2023
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, Pressure, Note, Lubabegron, Debt-to-GDP ratio, Research, ERP, North American Pet Health Insurance Association, EBITDA, Farm Animal, EPS, Video game, Pharmaceutical industry, Elanco

Asset impairment, restructuring and other special charges were $35 million in the second quarter of 2023 compared to $86 million in the second quarter of 2022.

Key Points: 
  • Asset impairment, restructuring and other special charges were $35 million in the second quarter of 2023 compared to $86 million in the second quarter of 2022.
  • Other expense was $23 million in the second quarter of 2023, compared with income of $6 million in the second quarter of 2022.
  • The adjusted effective tax rate increased to 19.9% in the second quarter of 2023 compared to 13.2% in the second quarter of 2022, primarily driven by the jurisdictional mix of Elanco earnings and certain favorable return to provision adjustments that impacted the second quarter of 2022.
  • Adjusted EBITDA was $222 million in the second quarter of 2023, a 27% decrease compared to the second quarter of 2022.

Elanco Releases 2022 Environmental, Social and Governance Report, Demonstrating Sustainability Progress in Internal Operations and Customer Collaborations

Retrieved on: 
Thursday, July 20, 2023
Environmental, Social and Governance (ESG), Green Technology, Sustainability, Pharmaceutical, Professional Services, Philanthropy, Environment, Pets, Agriculture, Natural Resources, Fund Raising, DEI (Diversity, Equity and Inclusion), Other Philanthropy, Veterinary, Consumer, Health, Knowledge, DSM, Partnership, GALVmed, Animal, Chronic kidney disease, Culture, Farmer, Electricity, Diabetes, Woman, Livestock, GHG, Global warming potential, Social Security Government Pension Offset, Milk, Acaricide, ELAN, Notifiable disease, Collection, USDA, Pet, ESG, Growth, Social, Transport, FDA, Meat, Food security, NYSE, Global Alliance, Food, EKS, Farm, Cat, Pharmaceutical industry, Vaccine, Renewable energy, Elanco

Elanco Animal Health Incorporated (NYSE:ELAN) today released its 2022 Environmental, Social and Governance (ESG) Report highlighting enhanced governance, transparency and progress measurements.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE:ELAN) today released its 2022 Environmental, Social and Governance (ESG) Report highlighting enhanced governance, transparency and progress measurements.
  • Through numerous internal initiatives and external collaborations within each pillar, Elanco is working to positively impact global concerns such as food security and nutrition, human health and well-being, and environmental sustainability.
  • Sourced approximately 12% of electricity from renewable sources in 2022, delivering significant progress on the company’s goal of 100% renewable electricity by 2030.
  • Donated more than $4M in combined corporate, foundation and employee charitable and community giving – benefiting more than 350 community organizations.

Elanco Confirms Date and Conference Call for Second Quarter 2023 Financial Results Announcement

Retrieved on: 
Tuesday, July 18, 2023
Health, Other Natural Resources, Consumer, Agriculture, Natural Resources, Pets, Veterinary, ELAN, Elanco, NYSE, Rare-earth element, Online shopping, Video game

Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2023 financial results on Monday, August 7, 2023.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2023 financial results on Monday, August 7, 2023.
  • Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
  • The conference call will begin at 8:00 a.m. eastern time.
  • Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco’s website on our events and presentations page.

Environmental Protection Agency (EPA) Completes Review of Seresto® Collar and Confirms Continued Registration; Data Affirms Safety Profile of the Product

Retrieved on: 
Thursday, July 13, 2023
Veterinary, Environment, Environmental Policy, FDA, Pets, Pharmaceutical, Consumer, Health, Agriculture, Natural Resources, Federal Insecticide, Fungicide, and Rodenticide Act, American Veterinary Medical Association, Human, Elanco, Lyme disease, Flea, Skin, Innovation, Multimedia, Tick, Thought, EPA, Incidence, Criticism of the Food and Drug Administration, ELAN, Nature, Risk, Pet, Toxicology, NYSE, Food, Dietary supplement, Vaccine

Comprehensive data affirms the safety profile of Seresto.

Key Points: 
  • Comprehensive data affirms the safety profile of Seresto.
  • View the full release here: https://www.businesswire.com/news/home/20230713309283/en/
    As part of EPA’s scientific review process, the agency analyzed incident data including third-party assessments and compared data to other EPA-registered pet products.
  • Following the comprehensive review, Elanco and EPA developed a stewardship program that Elanco will implement as a leader in the collar category.
  • “We stand behind more than a decade of science-based data, analysis and monitoring which affirms the safety profile of Seresto.

OLAPLEX Appoints Global Consumer Industry Veteran John P. Bilbrey to Board of Directors

Retrieved on: 
Tuesday, July 11, 2023
Partnership, Hershey, Elanco, Chairperson, Senior, JP, National Science Board, Campbell Soup Company, Bilbrey, Procter & Gamble, Kansas State University, Colgate-Palmolive, The Hershey Company, McCormick, Retirement, Chanel, McCormick & Company, Advent International, Professional Football Compensation Committee, Family, Compensated emancipation, Chair, Non-executive director, Management, Tapestry, Psychology

SANTA BARBARA, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- Olaplex Holdings, Inc. (NASDAQ: OLPX) ("OLAPLEX" or the "Company"), today announced that it has appointed John P. "JP" Bilbrey to the Company’s Board of Directors (the “Board”).

Key Points: 
  • SANTA BARBARA, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- Olaplex Holdings, Inc. (NASDAQ: OLPX) ("OLAPLEX" or the "Company"), today announced that it has appointed John P. "JP" Bilbrey to the Company’s Board of Directors (the “Board”).
  • A seasoned and accomplished executive within the global consumer space, Mr. Bilbrey will serve in the newly created role of Executive Chair of the Board.
  • “We’re thrilled to welcome JP to the Board and broader OLAPLEX family,” said JuE Wong, OLAPLEX’s President and Chief Executive Officer.
  • Mr. Bilbrey serves on the Board of Directors of Tapestry, Campbell Soup Company, Elanco Animal Health and Colgate-Palmolive, and previously served on the board of McCormick & Company.

Elanco Animal Health Reports First Quarter 2023 Results

Retrieved on: 
Tuesday, May 9, 2023
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, Vaccine, Pressure, Poultry, Research, ERP, North American Pet Health Insurance Association, EBITDA, Farm Animal, Growth, EPS, Adjustment, Pharmaceutical industry, Video game, Elanco, Aqua

Similar to the Pet Health business, Farm Animal revenue improved sequentially from the 3% constant currency decline in the fourth quarter of 2022.

Key Points: 
  • Similar to the Pet Health business, Farm Animal revenue improved sequentially from the 3% constant currency decline in the fourth quarter of 2022.
  • Charges recorded in the first quarter of 2023 primarily related to costs associated with the implementation of new systems, programs and processes due to the integration of Bayer Animal Health.
  • Reported and adjusted net interest expense was $64 million in the first quarter of 2023, an increase of $12 million, compared to the first quarter of 2022.
  • Adjusted EBITDA was $379 million in the first quarter of 2023, a 12% increase compared to the first quarter of 2022.

ADM Elects Directors at Annual Meeting, Declares Dividend

Retrieved on: 
Thursday, May 4, 2023
Other Professional Services, Agriculture, Professional Services, Natural Resources, ADM, Innovation, Animal, Elanco, NYSE, Management

ADM (NYSE: ADM), a global leader in human and animal nutrition, today announced at its Annual Stockholders’ Meeting the election of its board of directors, including new director Dr. Ellen de Brabander.

Key Points: 
  • ADM (NYSE: ADM), a global leader in human and animal nutrition, today announced at its Annual Stockholders’ Meeting the election of its board of directors, including new director Dr. Ellen de Brabander.
  • De Brabander brings a broad scientific background and deep R&D and innovation experience in human nutrition, life sciences and animal health to the Board.
  • In addition, ADM’s Board of Directors declared a cash dividend of 45.0 cents per share on the company’s common stock.
  • The dividend is payable on June 7, 2023, to shareholders of record on May 17, 2023.

Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus

Retrieved on: 
Tuesday, May 2, 2023
Health, Consumer, Infectious Diseases, Pets, Pharmaceutical, Veterinary, Vaccine, Therapy, U.S. Department of Defense Strategy for Operating in Cyberspace, Education, Hospital, Parvoviridae, Veterinarian, Multimedia, U.S. Department of Agriculture Cotton Annex, ELAN, USDA, Dog, Pet, Mortality, Nursing care plan, DVM, NYSE, First Ever, Disease, Elanco

View the full release here: https://www.businesswire.com/news/home/20230427005591/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230427005591/en/
    First and only monoclonal antibody treatment that targets canine parvovirus.
  • (Photo: Business Wire)
    With an estimated 330,000 cases of canine parvovirus available for treatment in the U.S. annuallyii, clinical trials demonstrate that the Canine Parvovirus Monoclonal Antibody single, intravenous dose delivers targeted efficacy in treating this deadly disease.
  • The treatment can be administered to dogs eight weeks of age or older with canine parvovirus.
  • Elanco will also continue to provide canine parvovirus education and resources to veterinarians, shelter owners and pet parents.

Elanco Confirms Date and Conference Call for First Quarter 2023 Financial Results Announcement

Retrieved on: 
Tuesday, April 18, 2023
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, ELAN, Elanco, NYSE, Rare-earth element, Video game

Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2023 financial results on Tuesday, May 9, 2023.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2023 financial results on Tuesday, May 9, 2023.
  • Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
  • The conference call will begin at 8:00 a.m. eastern time.
  • Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco’s website at https://investor.elanco.com/events-and-presentations/default.aspx .

Seresto® Launches Season Pass Guide to Ensure Pest-Free Spring

Retrieved on: 
Thursday, March 23, 2023
Parent, Flea, American Kennel Club, Life, Pet, CPO, Tick, Trapping, Cereal, Elanco

GREENFIELD, Ind., March 23, 2023 /PRNewswire/ -- With spring around the corner, the season's change brings the constant threat of fleas and ticks. To ensure a pest-free year, Seresto®, the No. 1 selling, veterinarian-recommended, non-prescription flea and tick collar with eight months of continuous protection, is launching its pet-approved spring Season Pass guide. The guide is designed to equip pet owners with the expert information they need to protect their four-legged companion from pests and keep experiencing joy. 

Key Points: 
  • 1 selling, veterinarian-recommended, non-prescription flea and tick collar with eight months of continuous protection, is launching its pet-approved spring Season Pass guide .
  • The guide is designed to equip pet owners with the expert information they need to protect their four-legged companion from pests and keep experiencing joy.
  • With the proper protection in place, it's time to enjoy the best the spring season has to offer with your four-legged friend.
  • As part of its Season Pass guide, Seresto® shares its list of top veterinarian-approved activities to enjoy during the springtime.